Repertoire Immune Medicines announced that the first participant has been dosed in a Phase I/II trial of RPTR-1-201, a TCR bispecific therapy designed to treat adults with advanced solid tumors, with the RPTR-1-201 clinical trial now enrolling at multiple sites across the United States and Europe following FDA IND clearance and European CTIS authorization. The Cambridge, Massachusetts-based company described the milestone as the first clinical entry for an asset derived from its proprietary DECODE platform, which maps interactions between T cell receptors and their target epitopes to identify candidates for development.
RPTR-1-201 is constructed from an engineered TCR that binds a tumor-selective epitope shared across multiple solid tumor types, coupled to an anti-CD3 moiety intended to engage and redirect endogenous T cells toward tumor cells. No clinical safety or efficacy data were reported at this stage; the announcement reflects a trial initiation milestone only. In preclinical studies, the company said RPTR-1-201 demonstrated killing activity in both immunologically active and poorly infiltrated tumor models, alongside a favorable preclinical safety profile, though these findings have not been reported in peer-reviewed literature.
The Phase I/II trial (NCT07293754) is an open-label, multi-site study enrolling adults with advanced solid tumors across dose-escalation and dose-expansion phases. The trial evaluates RPTR-1-201 both as monotherapy and in combination with an anti-PD-1 monoclonal antibody; the specific anti-PD-1 agent was not disclosed. Enrollment is ongoing, and total planned enrollment size was not stated in the source material. No interim efficacy or safety data are available, and the data remain at the pre-readout stage based solely on the first participant having been dosed.
RPTR-1-201 enters a competitive landscape that includes approved T-cell–redirecting therapies in specific solid tumor subtypes, though cross-trial comparisons are limited by differences in study design, tumor type, and patient populations. Tebentafusp, a gp100×CD3 TCR bispecific approved for metastatic uveal melanoma, demonstrated an overall survival hazard ratio of 0.51 versus investigator's choice in that disease. Tarlatamab, a DLL3×CD3 T-cell engager approved for previously treated small-cell lung cancer, achieved an overall response rate of 40% in its pivotal dataset. RPTR-1-201's basket design targeting a shared pan-tumor epitope distinguishes its development approach from these tumor-type-specific programs, though whether that breadth translates to clinical activity across indications remains to be established in the current trial.
Spot something wrong? Report an issue with this article